Injectable disease modifying agents in multiple sclerosis: pattern of medication use and clinical effectiveness (original) (raw)
Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database
Genevieve Laforet
International journal of MS care, 2013
View PDFchevron_right
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study
Jeptha Davenport
PloS one, 2015
View PDFchevron_right
Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice
Anne Cross
Multiple sclerosis journal - experimental, translational and clinical
View PDFchevron_right
First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence
Eleonora Baldi
Current medical research and opinion, 2018
View PDFchevron_right
Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment
Karin Van Der Hiele
Patient Preference and Adherence, 2016
View PDFchevron_right
Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability
tracey weiland
Neurological research, 2015
View PDFchevron_right
Differences In Multiple Sclerosis Relapse Rates Based On Patient Adherence, Average Daily Dose, And Persistence With Disease-Modifying Therapy: Observations Based on Real-World Data
Augusto Grinspan
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2015
View PDFchevron_right
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register
Damiano Paolicelli
Neurotherapeutics, 2021
View PDFchevron_right
Early predictors of injectable disease modifying drugs suboptimal response based on clinical and radiological data assessment in Polish Multiple Sclerosis patients
Dorota Koziarska
Neurologia i Neurochirurgia Polska
View PDFchevron_right
Predictors of first-line treatment persistence in a Portuguese cohort of relapsing-remitting multiple sclerosis
Sonia Batista
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2016
View PDFchevron_right
When and how disease-modifying drugs for multiple sclerosis should be changed in daily practice
Ryotaro Ikeguchi
Clinical and Experimental Neuroimmunology, 2017
View PDFchevron_right
Changes in the Multiple Sclerosis Treatment Paradigm. What Do We Do Now and What Were We Doing Before?
Bárbara Eizaguirre
Journal of clinical neurology (Seoul, Korea), 2018
View PDFchevron_right
Influence of treatments in multiple sclerosis disability: A cohort study
Paolo Contu
Multiple Sclerosis Journal, 2014
View PDFchevron_right
A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study
Eleonora Cocco
Journal of neurology, 2018
View PDFchevron_right
Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis
Sayeedul Hasan Arif
Cureus
View PDFchevron_right
High-efficacy therapies for relapsing-remitting multiple sclerosis: implications for adherence. An expert opinion from the United Arab Emirates
Jihad Inshasi
Neurodegenerative Disease Management, 2020
View PDFchevron_right
Injectable Multiple Sclerosis Medications
Zung Tran
International Journal of MS Care, 2012
View PDFchevron_right
Medication Adherence, Persistence and Cost in Multiple Sclerosis Patients: Oral vs Parenteral Treatment
andrea logreco
International Journal of Pharmaceutical Sciences Research
View PDFchevron_right
Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS
Martin Valis
Multiple Sclerosis and Related Disorders, 2019
View PDFchevron_right
Fostering adherence to injectable disease-modifying therapies in multiple sclerosis
Alessandra Lugaresi, Francesco Patti
Expert Review of Neurotherapeutics, 2014
View PDFchevron_right
An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014–2017
bruno detournay
Multiple Sclerosis and Related Disorders, 2020
View PDFchevron_right
Course of therapy in patients with active relapsing-remitting multiple sclerosis despite first-line treatment
Anna Smaga
Postępy Psychiatrii i Neurologii
View PDFchevron_right
Highly active disease and access to disease-modifying treatments in patients with relapsing-remitting multiple sclerosis in Poland
Anna Smaga
Neurologia i Neurochirurgia Polska
View PDFchevron_right
Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients
Michele Mass
Multiple Sclerosis, 2005
View PDFchevron_right
Influence of treatment in multiple sclerosis dysability: an open, retrospective, non-randomized long-term analysis
Cláudia Kay
Arquivos de Neuro-Psiquiatria, 2010
View PDFchevron_right
Epidemiology of Pharmacological Treatment of Multiple Sclerosis in Croatia
Sanja Tomasovic
2019
View PDFchevron_right
Saudi Consensus Recommendations on the Management of Multiple Sclerosis: Disease-Modifying Therapies and Management of Relapses
Eslam Shosha
Clinical and Translational Neuroscience
View PDFchevron_right
Variations in multiple sclerosis practice within Europe – Is it time for a new treatment guideline?
livia sousa
Multiple Sclerosis and Related Disorders, 2016
View PDFchevron_right
Adherence to Disease-Modifying Agents and Association with Quality of Life Among Patients with Relapsing-Remitting Multiple Sclerosis
Jennifer Lafata
International Journal of MS Care, 2010
View PDFchevron_right